GSA Capital Partners LLP Lowers Holdings in ProKidney Corp. $PROK

GSA Capital Partners LLP trimmed its stake in ProKidney Corp. (NASDAQ:PROK) by 67.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 168,031 shares of the company’s stock after selling 342,584 shares during the quarter. GSA Capital Partners LLP owned 0.06% of ProKidney worth $407,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of PROK. Zullo Investment Group Inc. purchased a new position in shares of ProKidney in the 3rd quarter worth about $28,000. AQR Capital Management LLC raised its holdings in ProKidney by 106.4% in the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock worth $46,000 after buying an additional 27,098 shares during the last quarter. Catalyst Funds Management Pty Ltd bought a new position in shares of ProKidney in the second quarter worth approximately $36,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of ProKidney during the second quarter valued at approximately $208,000. Finally, Marshall Wace LLP purchased a new stake in shares of ProKidney during the second quarter valued at approximately $274,000. 51.59% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on PROK shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a research report on Thursday, January 22nd. HC Wainwright initiated coverage on ProKidney in a report on Tuesday, December 16th. They set a “buy” rating and a $12.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $7.40.

ProKidney Trading Up 0.9%

NASDAQ:PROK opened at $2.26 on Thursday. The company has a market cap of $679.88 million, a PE ratio of -4.11 and a beta of 1.78. The company has a 50 day simple moving average of $2.19 and a two-hundred day simple moving average of $2.44. ProKidney Corp. has a 12 month low of $0.46 and a 12 month high of $7.13.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.